Calhm2-flox Mouse
一般名
Calhm2-flox
製品ID
S-CKO-15544
背景情報
C57BL/6JCya
系統ID
CKOCMP-72691-Calhm2-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Calhm2-flox Mouse(カタログ番号S-CKO-15544)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Calhm2-flox
系統ID
CKOCMP-72691-Calhm2-B6J-VA
遺伝子名
製品ID
S-CKO-15544
遺伝子別名
Fam26b, 2810048G17Rik
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conditional knockout
染色体
Chr 19
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000035822
NCBIトランスクリプトID
NM_133746
ターゲット領域
Exon 2
有効領域の大きさ
~1.4 kb
遺伝子研究の概要
Calhm2, or calcium homeostasis modulator family protein 2, is involved in multiple biological functions. It has been linked to processes like mitochondrial protein import, regulating fatty acid metabolism as it serves as the import channel for the ECHA subunit of the mitochondrial trifunctional protein [4]. It is also associated with extracellular ATP release, which is crucial for cell-to-cell signaling in the brain [7].
In various disease-related studies using knockout (KO) mouse models, Calhm2 has shown significant impacts. In Alzheimer's disease (AD) 5×FAD mice, both conventional and conditional microglial knockout of Calhm2 reduced amyloid β deposition, neuroinflammation, and cognitive impairments by inhibiting microglial pro-inflammatory activity and increasing phagocytic activity [1]. In Parkinson's disease (PD) model mice, conventional and microglial Calhm2 knockout decreased dopaminergic neuronal loss and microglial numbers, improving locomotor performance by inhibiting EFHD2-STAT3 signaling in microglia [3]. In models of depressive-like behaviors, conventional and conditional astrocyte knockout of Calhm2 led to reduced ATP concentrations, neural dysfunction, and depression-like behaviors, which could be rescued by ATP replenishment [7]. Also, the CALHM2 V136G mutation in a mouse model was associated with depressive-like behaviors and cognitive decline in old age, with the mutation causing loss of CALHM2 ATP-release function in astrocytes [2]. In addition, in a chronic inflammation pain model, knockdown of Calhm2 in the anterior cingulate cortex reversed pain behaviors and comorbid anxiety symptoms [6]. For NK cell-based immunotherapies, CALHM2-knockout NK cells showed enhanced cytotoxicity and tumor infiltration in mouse primary NK cells and human chimeric antigen receptor (CAR)-NK cells [5,8].
In conclusion, Calhm2 plays essential roles in multiple biological processes and is involved in various disease conditions. Studies using KO and conditional knockout mouse models have revealed its significance in microglial activation, neurodegenerative diseases like AD and PD, mood-related disorders, pain-related anxiety, and NK cell-based immunotherapies, providing potential therapeutic targets for these diseases.
References:
1. Cheng, Jinbo, Dong, Yuan, Ma, Jun, Yu, Ye, Yuan, Zengqiang. 2021. Microglial Calhm2 regulates neuroinflammation and contributes to Alzheimer's disease pathology. In Science advances, 7, . doi:10.1126/sciadv.abe3600. https://pubmed.ncbi.nlm.nih.gov/34433553/
2. Liao, Yang, Wang, Yingyi, Tao, Qing-Qing, Pan, Rui-Yuan, Yuan, Zengqiang. 2023. CALHM2 V136G polymorphism reduces astrocytic ATP release and is associated with depressive symptoms and Alzheimer's disease risk. In Alzheimer's & dementia : the journal of the Alzheimer's Association, 19, 4407-4420. doi:10.1002/alz.13366. https://pubmed.ncbi.nlm.nih.gov/37493186/
3. Bo, Xuena, Xie, Fei, Zhang, Jingdan, Yuan, Zengqiang, Cheng, Jinbo. 2023. Deletion of Calhm2 alleviates MPTP-induced Parkinson's disease pathology by inhibiting EFHD2-STAT3 signaling in microglia. In Theranostics, 13, 1809-1822. doi:10.7150/thno.83082. https://pubmed.ncbi.nlm.nih.gov/37064868/
4. Jonas, Elizabeth, Mnatsakanyan, Nelli, Rivera-Molina, Felix, Caplan, Michael, Khokha, Mustafa. 2024. CALHM2 is a mitochondrial protein import channel that regulates fatty acid metabolism. In Research square, , . doi:10.21203/rs.3.rs-4985689/v1. https://pubmed.ncbi.nlm.nih.gov/39315269/
5. Peng, Lei, Renauer, Paul A, Sferruzza, Giacomo, Ye, Lupeng, Chen, Sidi. 2024. In vivo AAV-SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy. In Nature biotechnology, , . doi:10.1038/s41587-024-02282-4. https://pubmed.ncbi.nlm.nih.gov/38918616/
6. Li, Xiaohui, Xiong, Mengyuan, Gao, Yan, Xu, Xueqin, Ke, Changbin. 2023. Upregulation of Calhm2 in the anterior cingulate cortex contributes to the maintenance of bilateral mechanical allodynia and comorbid anxiety symptoms in inflammatory pain conditions. In Brain research bulletin, 204, 110808. doi:10.1016/j.brainresbull.2023.110808. https://pubmed.ncbi.nlm.nih.gov/37926398/
7. Ma, J, Qi, X, Yang, C, Zhang, C, Yuan, Z. 2017. Calhm2 governs astrocytic ATP releasing in the development of depression-like behaviors. In Molecular psychiatry, 23, 883-891. doi:10.1038/mp.2017.229. https://pubmed.ncbi.nlm.nih.gov/29180673/
8. Peng, Lei, Renauer, Paul A, Ye, Lupeng, Lam, Stanley Z, Chen, Sidi. 2023. Perturbomics of tumor-infiltrating NK cells. In bioRxiv : the preprint server for biology, , . doi:10.1101/2023.03.14.532653. https://pubmed.ncbi.nlm.nih.gov/36993337/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
